US Stock MarketDetailed Quotes

RXRX Recursion Pharmaceuticals

Watchlist
  • 8.340
  • +0.200+2.46%
Close Feb 26 16:00 ET
  • 8.750
  • +0.410+4.92%
Pre 06:09 ET
3.26BMarket Cap-5.42P/E (TTM)

Recursion Pharmaceuticals Key Stats

Recursion Pharmaceuticals Q4 2024 Estimates Date

Currency:USDFeb 28, 2025

Estimate YoY
Revenue
19.04M
+74.85%
EPS
-0.46
-8.76%
Buy

Feb 6, 2025

Recursion Pharmaceuticals Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 3 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 12.000M--
Feb 28, 20252024/Q4-- / 19.043M--
Nov 6, 20242024/Q326.082M / 29.829M--
Aug 8, 20242024/Q214.417M / 13.286M--
May 9, 20242024/Q113.794M / 13.067M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 12.000M--
Feb 28, 20252024/Q4-- / 19.043M--
Nov 6, 20242024/Q326.082M / 29.829M--
Aug 8, 20242024/Q214.417M / 13.286M--
May 9, 20242024/Q113.794M / 13.067M--

Unlock Free Earnings Estimates

Recursion Pharmaceuticals Earnings Reports

Read more

Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Analysis

Analyst Rating

Updated: Feb 6, 2025

Buy

  • Buy

    40.00%
  • Hold

    60.00%
  • Sell

    0.00%

Price Target

No Data